National Kidney Foundation Innovation Fund Invests in ImmunoFree
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund. The fund will support ImmunoFree, a pioneering biomedical company dedicated to reshaping the landscape of organ transplantation by eliminating the need for immunosuppressive medications.
- ~
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund. - "In a post COVID world, solving the issues raised by immunosuppressive medications for transplant patients has never been more critical," said Kevin Longino, CEO of the National Kidney Foundation and a kidney transplant recipient.
- Launched in 2021, the NKF Innovation Fund works to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve.
- The fund invests in early to mid-stage companies that are developing innovative, patient-centric kidney therapies.